Opendata, web and dolomites

RELEASE

Nanofiber based drug delivery for surgical therapy of adult and paediatric solid tumours

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RELEASE" data sheet

The following table provides information about the project.

Coordinator
CEBIOTEX SL 

Organization address
address: CALLE BALDIRI I REIXAC 4 - 8 PARC CIENTIFIC BARCELONA
city: BARCELONA
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.cebiotex.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CEBIOTEX SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

Cebiotex is a company founded by medical business entrepreneurs plus experts from the biomedical nano-fibre plus oncology sectors. With experts from a world leading hospital in cancer treatment(Sant Joan de Déu) and researchers from the Universitat Politecnica de Catalunya, we have been steadily developing our technology and single minded vision for several years.

Our patented process allows for a unique method for depositing of active agents between nano-fibres. The resultant flexible, biodegradable nano-gauze will be able to radically improve treatments across multiple fields. Our first product line uses the highly potent and promising anti-cancer drug, SN-38. Until now, the low solubility of a drug such as SN-38 has withheld its adoption because standard drug delivery mechanisms fail. We turn the problem on its head, using our proprietary gauze we hold the active agent in place next to the treatment area, taking advantage of the low solubility of such drugs to provide constant high dosage to targeted cells over 4 weeks.

With a focus on this initial cancer cell therapy control drug, we have a vision to use this as a spearhead to firmly plant ourselves in the European medical biotech sector.

We request targeted SME Instrument funding in order to fully prepare the commercial groundwork for our vision to become a leading drug delivery platform organisation and to finalise plans to move our first product from pre-clinical to phase I/II trials. By challenging all of our assumptions we wish to confirm our predictions for a solid business, solid employment growth and a new nano-tech drug development specialism in Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RELEASE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RELEASE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More